TL;DR
Get pet supplies delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
IDEXX Laboratories announced that mast cell tumor detection is now available in North America through its IDEXX Cancer Dx Panel for dogs. The blood test is intended for apparently healthy dogs at increased cancer risk and is run alongside wellness testing; a positive result requires veterinary assessment and further diagnostic investigation.
IDEXX Laboratories has made mast cell tumor detection available in North America as part of its Cancer Dx Panel for dogs, expanding a screening service that already includes lymphoma detection. The company says the panel can be run with routine wellness blood testing, using the same blood collection, and is intended for apparently healthy dogs at increased risk of cancer.
The panel is designed to look for cancer-associated signals in blood, according to IDEXX. The company says the expanded test is intended to identify signals associated with specific cancers, rather than provide only a generalized indication of cancer risk. A positive result is not a diagnosis: IDEXX says it should be followed by a veterinary clinical assessment and further diagnostic investigation.
IDEXX recommends screening for senior dogs aged 7 and older, as well as dogs from breeds predisposed to cancer beginning at age 4. The examples listed by the company include Golden Retrievers, Labrador Retrievers, Boxers and German Shepherds. The recommendation concerns screening eligibility; it does not mean every dog in those groups has cancer or will develop it.
When ordered with the most commonly used IDEXX Reference Laboratories wellness screening panels, the company lists a practice price of about US$15, or C$21. The amount charged to pet owners is set by individual veterinary practices. IDEXX describes the mast cell tumor addition as the next step toward a broader canine cancer screening panel.
Adding Cancer Screening to Wellness Visits
The expansion gives veterinary practices another blood-based screening option to discuss during routine care, including visits for dogs that appear healthy. IDEXX says no additional blood draw is needed when the Cancer Dx Panel is run alongside wellness testing. That may make it easier to include the test within an existing appointment, though the company’s announcement does not establish how widely clinics will adopt it or how many owners will choose it.
The stated focus on aggressive, clinically significant tumors matters because screening can prompt follow-up before an owner notices a lump or other change. However, the announcement does not provide performance figures for the mast cell tumor component, such as sensitivity, specificity or the rate of positive results requiring additional testing. The practical value for an individual dog will depend on veterinary interpretation and what further investigation finds.
For owners, the distinction between a screening result and a diagnosis is central. A positive result is a signal to consult a veterinarian and investigate further, not confirmation that a dog has cancer. Screening also cannot be treated as a guarantee that a dog without a positive result is cancer-free.
As an affiliate, we earn on qualifying purchases.
From Lymphoma Toward Broader Screening
The Cancer Dx Panel previously offered canine lymphoma screening, according to IDEXX’s announcement. Adding mast cell tumor detection extends the panel to another cancer type and is part of the company’s stated aim to build a broader multi-cancer screening service for dogs. The release presents the new availability as an expansion of the existing panel rather than a standalone diagnostic test.
IDEXX cites an estimate that one in four dogs will face cancer during their lifetime. That figure is presented in the company’s press release; it is a lifetime estimate, not a measure of how many dogs currently have cancer or how well this panel detects it. The company also frames the test around the possibility that some dogs show few or no obvious signs early in disease, which is why it is aimed at screening apparently healthy dogs at increased risk.
The planned next addition is hemangiosarcoma detection. IDEXX says it expects that screening to be available to clinics across North America in December 2026. That is a future availability date stated by the company, not a currently available feature of the panel.
What the Announcement Does Not Show
IDEXX’s announcement does not report accuracy or validation figures for mast cell tumor detection, including the test’s sensitivity, specificity, or false-positive and false-negative rates. It also does not describe the clinical studies or patient populations used to evaluate this component. Without those details, readers cannot judge the test’s performance from the announcement alone.
The release does not specify how often a positive result leads to a confirmed tumor, what diagnostic procedures may be needed in each case, or whether a negative result can rule out disease. IDEXX says positive results should prompt clinical assessment and further investigation, but the exact next steps will depend on the dog and the veterinarian’s findings.
It is also not clear how many practices currently offer the expanded panel or what pet owners will pay. The listed figure is a price to veterinary practices when the test is bundled with certain IDEXX wellness panels; retail pricing is set by each practice.
Clinic Rollout and Planned Expansion
Veterinary practices can order the panel with lymphoma and mast cell tumor detection through IDEXX Reference Laboratories, according to the company. Owners considering screening can ask their veterinarian whether the test is available, whether their dog fits the company’s suggested risk groups, and what follow-up would be appropriate for either a positive or negative result.
IDEXX has announced December 2026 as the planned North American availability date for hemangiosarcoma detection. The company describes that addition as a further expansion of the panel. The announcement does not provide further rollout milestones or clinical details for the planned test.
Key Questions
What has IDEXX added to its Cancer Dx Panel?
IDEXX says mast cell tumor detection is now available in North America, joining the panel’s existing canine lymphoma screening.
Does a positive result mean a dog has cancer?
No. IDEXX says a positive result identifies a cancer-specific signal and should be followed by veterinary assessment and further diagnostic investigation. It is not, by itself, a confirmed diagnosis.
Which dogs does IDEXX recommend screening?
The company recommends screening for senior dogs aged 7 and older and predisposed breeds aged 4 and older. Listed examples include Golden Retrievers, Labrador Retrievers, Boxers and German Shepherds. Owners should discuss suitability with a veterinarian.
Does the test require another blood draw?
IDEXX says the panel can be run using blood collected alongside routine wellness testing, with no additional blood draw required when ordered with that testing.
When is hemangiosarcoma detection expected?
IDEXX says hemangiosarcoma detection is planned to become available to clinics across North America in December 2026. The company has not presented it as currently available.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
